Home > > Asia And Global Gene Therapy Market- Size, Share, Growth Rate, and Forecast
TABLE OF CONTENTS CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: ASIA GENE THERAPY MARKET 3.1. OVERVIEW 3.2. ASIA 3.2.1. ASIA GENE THERAPY MARKET, BY VECTOR 3.2.2. ASIA GENE THERAPY MARKET, BY INDICATION 3.2.3. ASIA GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4. ASIA GENE THERAPY MARKET, BY COUNTRY 3.2.4.1. JAPAN 3.2.4.1.1. JAPAN GENE THERAPY MARKET, BY VECTOR 3.2.4.1.2. JAPAN GENE THERAPY MARKET, BY INDICATION 3.2.4.1.3. JAPAN GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.2. CHINA 3.2.4.2.1. CHINA GENE THERAPY MARKET, BY VECTOR 3.2.4.2.2. CHINA GENE THERAPY MARKET, BY INDICATION 3.2.4.2.3. CHINA GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.3. ROAPAC 3.2.4.3.1. ROAPAC GENE THERAPY MARKET, BY VECTOR 3.2.4.3.2. ROAPAC GENE THERAPY MARKET, BY INDICATION 3.2.4.3.3. ROAPAC GENE THERAPY MARKET, BY DELIVERY METHOD CHAPTER 4: GLOBAL GENE THERAPY MARKET, BY VECTOR 4.1. OVERVIEW 4.2. NON-VIRAL VECTORS 4.2.1. NON-VIRAL VECTORS MARKET, BY REGION 4.2.1.1. NORTH AMERICA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.2. EUROPE NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.3. ASIA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.3. VIRAL VECTORS 4.3.1. VIRAL VECTORS MARKET, BY REGION 4.3.1.1. NORTH AMERICA VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.2. EUROPE VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.3. ASIA VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET, BY COUNTRY CHAPTER 5: GLOBAL GENE THERAPY MARKET, BY INDICATION 5.1. OVERVIEW 5.2. NEUROLOGICAL DISEASES 5.2.1. NEUROLOGICAL DISEASES MARKET, BY REGION 5.2.1.1. NORTH AMERICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.2. EUROPE NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.3. ASIA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.3. CANCER 5.3.1. CANCER MARKET, BY REGION 5.3.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 5.3.1.2. EUROPE CANCER MARKET, BY COUNTRY 5.3.1.3. ASIA CANCER MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 5.4. HEPATOLOGICAL DISEASES 5.4.1. HEPATOLOGICAL DISEASES MARKET, BY REGION 5.4.1.1. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.2. EUROPE HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.3. ASIA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.4. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.5. DUCHENNE MUSCULAR DYSTROPHY 5.5.1. DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION 5.5.1.1. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.2. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.3. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.4. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.6. OTHER INDICATIONS 5.6.1. OTHER INDICATIONS MARKET, BY REGION 5.6.1.1. NORTH AMERICA OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.2. EUROPE OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.3. ASIA OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.4. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET, BY COUNTRY CHAPTER 6: GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD 6.1. OVERVIEW 6.2. IN-VIVO GENE THERAOY 6.2.1. IN-VIVO GENE THERAOY MARKET, BY REGION 6.2.1.1. NORTH AMERICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.2. EUROPE IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.3. ASIA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3. EX-VIVO GENE THERAOY 6.3.1. EX-VIVO GENE THERAOY MARKET, BY REGION 6.3.1.1. NORTH AMERICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.2. EUROPE EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.3. ASIA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY FIGURE 124. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF TABLES TABLE 01. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 02. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 03. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 04. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 05. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 07. ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 08. ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 09. ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 10. JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 11. JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 12. JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 13. CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 14. CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 15. CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 16. ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 17. ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 18. ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 19. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 20. NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 21. NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 22. EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 23. ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 24. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 25. VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 26. NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 28. ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 30. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 31. NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 32. NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 37. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 42. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 47. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 51. OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 52. NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 56. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 57. IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 58. NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 61. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 62. EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 63. NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 01. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) FIGURE 02. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) FIGURE 03. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) FIGURE 04. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) FIGURE 05. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) FIGURE 06. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) FIGURE 07. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) FIGURE 08. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) FIGURE 09. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 10. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 11. TOP INVESTMENT POCKETS: JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 12. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 13. TOP INVESTMENT POCKETS: JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 14. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 15. TOP INVESTMENT POCKETS: JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 16. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 17. TOP INVESTMENT POCKETS: CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 18. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 19. TOP INVESTMENT POCKETS: CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 20. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 21. TOP INVESTMENT POCKETS: CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 22. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 23. TOP INVESTMENT POCKETS: ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 24. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 25. TOP INVESTMENT POCKETS: ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 26. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 27. TOP INVESTMENT POCKETS: ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 28. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 29. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 30. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 31. TOP INVESTMENT POCKETS: NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 32. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 33. TOP INVESTMENT POCKETS: NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 34. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 35. TOP INVESTMENT POCKETS: EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 36. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 37. TOP INVESTMENT POCKETS: ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 38. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 39. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 40. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 41. TOP INVESTMENT POCKETS: VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 42. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 43. TOP INVESTMENT POCKETS: NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 44. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 45. TOP INVESTMENT POCKETS: EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 46. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 47. TOP INVESTMENT POCKETS: ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 48. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 49. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 50. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 51. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 52. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 53. TOP INVESTMENT POCKETS: NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 54. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 55. TOP INVESTMENT POCKETS: NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 56. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 57. TOP INVESTMENT POCKETS: EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 58. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 59. TOP INVESTMENT POCKETS: ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 60. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 61. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 62. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 63. TOP INVESTMENT POCKETS: CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 64. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 65. TOP INVESTMENT POCKETS: NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 66. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 67. TOP INVESTMENT POCKETS: EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 68. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 69. TOP INVESTMENT POCKETS: ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 70. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 71. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 72. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 73. TOP INVESTMENT POCKETS: HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 74. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 75. TOP INVESTMENT POCKETS: NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 76. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 77. TOP INVESTMENT POCKETS: EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 78. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 79. TOP INVESTMENT POCKETS: ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 80. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 81. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 82. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 83. TOP INVESTMENT POCKETS: DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 84. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 85. TOP INVESTMENT POCKETS: NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 86. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 87. TOP INVESTMENT POCKETS: EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 88. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 89. TOP INVESTMENT POCKETS: ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 90. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 91. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 92. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 93. TOP INVESTMENT POCKETS: OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 94. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 95. TOP INVESTMENT POCKETS: NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 96. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 97. TOP INVESTMENT POCKETS: EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 98. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 99. TOP INVESTMENT POCKETS: ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 100. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 101. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 102. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 103. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 104. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 105. TOP INVESTMENT POCKETS: IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 106. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 107. TOP INVESTMENT POCKETS: NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 108. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 109. TOP INVESTMENT POCKETS: EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 110. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 111. TOP INVESTMENT POCKETS: ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 112. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 113. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 114. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 115. TOP INVESTMENT POCKETS: EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 116. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 117. TOP INVESTMENT POCKETS: NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 118. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 119. TOP INVESTMENT POCKETS: EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 120. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 121. TOP INVESTMENT POCKETS: ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 122. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 123. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 124. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF FIGURES FIGURE 01. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) FIGURE 02. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) FIGURE 03. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) FIGURE 04. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) FIGURE 05. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) FIGURE 06. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) FIGURE 07. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) FIGURE 08. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) FIGURE 09. TOP INVESTMENT POCKETS: ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 10. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 11. TOP INVESTMENT POCKETS: JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 12. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: JAPAN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 13. TOP INVESTMENT POCKETS: JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 14. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: JAPAN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 15. TOP INVESTMENT POCKETS: JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 16. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: JAPAN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 17. TOP INVESTMENT POCKETS: CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 18. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CHINA GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 19. TOP INVESTMENT POCKETS: CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 20. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CHINA GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 21. TOP INVESTMENT POCKETS: CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 22. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CHINA GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 23. TOP INVESTMENT POCKETS: ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 24. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ROAPAC GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 25. TOP INVESTMENT POCKETS: ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 26. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ROAPAC GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 27. TOP INVESTMENT POCKETS: ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 28. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ROAPAC GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) FIGURE 29. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 30. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) FIGURE 31. TOP INVESTMENT POCKETS: NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 32. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 33. TOP INVESTMENT POCKETS: NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 34. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 35. TOP INVESTMENT POCKETS: EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 36. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 37. TOP INVESTMENT POCKETS: ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 38. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 39. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 40. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 41. TOP INVESTMENT POCKETS: VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 42. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 43. TOP INVESTMENT POCKETS: NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 44. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 45. TOP INVESTMENT POCKETS: EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 46. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 47. TOP INVESTMENT POCKETS: ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 48. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 49. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 50. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 51. TOP INVESTMENT POCKETS: GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 52. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) FIGURE 53. TOP INVESTMENT POCKETS: NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 54. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 55. TOP INVESTMENT POCKETS: NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 56. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 57. TOP INVESTMENT POCKETS: EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 58. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 59. TOP INVESTMENT POCKETS: ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 60. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 61. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 62. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 63. TOP INVESTMENT POCKETS: CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 64. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) FIGURE 65. TOP INVESTMENT POCKETS: NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 66. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 67. TOP INVESTMENT POCKETS: EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 68. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 69. TOP INVESTMENT POCKETS: ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 70. INCREMENTAL OPPORTUNITY ANALYSIS PLOTTING: ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) FIGURE 71. TOP INVESTMENT POCKETS: MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COU